Docon encumbers Thyrocare bonus shares to secure API Holdings debentures

Docon Technologies Private Limited, a promoter of Thyrocare Technologies Limited, has disclosed the creation of a fresh encumbrance on bonus equity shares allotted by Thyrocare. On December 1, 2025, Thyrocare allotted bonus shares in a 2:1 ratio. Docon's encumbrance covers 6,46,46,464 newly allotted bonus shares.

The pledge is in favor of Catalyst Trusteeship Limited, acting as debenture trustee, to secure obligations of API Holdings Limited related to its secured, unlisted, redeemable non-convertible debentures. Before this transaction, Docon held 3,23,23,232 encumbered shares, representing 60.93% of Thyrocare's total share capital.

Following the bonus allotment and fresh encumbrance, the total number of encumbered shares held by Docon has increased to 9,69,69,696. Despite the increase, the percentage of encumbered shareholding remains unchanged at 60.93% of Thyrocare's total paid-up equity share capital. The total equity share capital of Thyrocare is 15,91,61,691 equity shares.